August 2024 in “Latin American Journal of Development” 5α-reductase enzymes are crucial in certain disorders, and while treatment advances exist, more research on SRD5A3 is needed.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
The treatment was not recommended due to limited effectiveness and significant side effects.
January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
6 citations
,
November 2017 in “Dermatologic Therapy” Combining mometasone furoate cream with adapalene gel is safer and more effective for hair regrowth in alopecia areata than using the cream alone.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
69 citations
,
December 2006 in “Archives of dermatology” Adalimumab may cause severe hair loss in some patients.
8 citations
,
December 1996 in “Dermatologic Surgery” Both ASR I and ASR II are effective scalp reduction techniques, with ASR I creating finer scars and ASR II removing more bald area and reducing stretch-back.
10 citations
,
March 2023 in “Journal of Managed Care & Specialty Pharmacy” Alopecia areata and atopic dermatitis have similar healthcare costs, but alopecia areata leads to more outpatient and long-term disability expenses.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
June 1985 in “Journal of the American Academy of Dermatology”
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
January 2008 in “프로그램북(구 초록집)”
1 citations
,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
2 citations
,
August 2014 in “Journal of dermatological science” Adapalene 0.1% effectively reduces acne by decreasing comedones and altering skin properties.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
2 citations
,
October 2025 in “Frontiers in Medicine” Isotretinoin has many serious side effects, including some new ones, needing better safety measures and updated labels.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
October 2023 in “Psychiatry research. Case reports” A new HRAS gene variant may cause a range of symptoms including intellectual disability and psychiatric issues.
6 citations
,
June 2011 in “British Journal of Dermatology” People with alopecia areata have higher levels of RBP4 protein and antibodies against it.
April 2025 in “International Journal of Clinical & Medical Case Studies” Dextroamphetamine may help treat alopecia areata.
September 2004 in “Hair transplant forum international” The ABHRS has outlined its goals for the next year.
January 2023 in “Pharmaceutics” AA–TF#15 significantly promotes hair regrowth and could be an effective treatment for androgenic alopecia.
6 citations
,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
September 2018 in “The Journal of Urology”